Skip to main content
. 2003 Jan;10(1):53–58. doi: 10.1128/CDLI.10.1.53-58.2003

TABLE 1.

Immunologic and virologic characteristics of the study patients

Patient no. Patient identification no. Age (yr) T-cell count
Virus load (RNA copies/ml) Treatment history (no. of drugs/duration [months])a Virologic/immunologic responseb
CD4
CD8
% Absolute % Absolute
1 6750001208 0.2 37 3,713 28 2,785 125,482 None NA
2 6750000964 2.0 17 1,420 39 3,178 <50 3/24 +/−
3 6750001154 2.6 19 443 25 590 141,213 2/1 −/−
4 6750001146 3.2 20 715 42 1,466 14,258 2/29 −/−
5 6750001085 4.9 29 1,067 39 1,559 41,000 None NA
6 6700000121 5.8 23 480 44 938 35,174 3/20 −/−
7 6750001028 6.8 29 708 38 918 79,267 3/2 −/+
8 6750000946 7.0 23 502 27 598 <50 3/9 +/−
9 6750000649 7.0 27 1,534 62 3,559 25,000 2/12 −/+
10 6750000939 8.0 33 600 41 749 5,028 3/12 +/+
11 6750000935 9.0 22 813 44 1,514 96,216 3/14 −/+
12 6700000116 9.0 29 1,312 45 2,061 13,391 3/16 −/+
13 6750000717 9.0 32 494 34 526 1,953 1/24 +/+
14 6750000860 9.5 34 1,134 39 1,234 >750,000 3/19 −/+
15 6700000087 10.6 19 277 23 343 39,979 3/6 −/+
16 6700000113 11.8 26 979 46 1,713 972 3/12 +/+
17 6700000061 13.1 23 964 45 1,928 600 4/3 +/−
18 6700000011 13.4 26 633 35 835 1,070 4/1 +/+
19 6700000129 13.7 38 677 36 637 9,161 2/12 −/+
20 6750000988 15.0 0 0 15 202 229,086 3/14 −/−
21 6750000626 15.5 38 1,064 49 1,389 128,628 2/7 −/+
22 6700000123 16.5 23 535 37 85 <50 4/22 +/−
a

Patients were on combinations of nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine [AZT], lamivudine [3TC], and didioxyinosine) or on NRTIs plus nonnucleoside reverse transcriptase inhibitors (Nevirapine or Efavirenz) or two NRTIs plus protease inhibitors (nelfinavir, ritonavir, or saquinavir) for two, three, or four drug combinations.

b

Virologic response was defined as a decrease in plasma HIV RNA of greater than 1.0 log or to undetectable levels or the continued state of an undetectable virus load. Immunologic response was defined as an increase in the percentage of CD4 greater than 10% or the continued maintainance of CD4 T cells at greater than 25%. NA, not applicable.